Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 3/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19769066 | 1.00 | ADRA2A (0.35) | ADRA2AADRA2BADRA2CKDRRET | |
| SCHEMBL20621302 | 0.85 | ADRA2A (0.33) | ADRA2AADRA2BADRA2CKDRADRA1D | |
| SCHEMBL21173560 | 0.81 | ALDH1A1 (0.33) | RET | |
| SCHEMBL22096855 | 0.75 | KDR (0.32) | ADRA2AADRA2BADRA2CKDRRET | |
| SCHEMBL24833024 | 0.75 | CCR1 (0.41) | — | |
| SCHEMBL19779245 | 0.75 | NOS3 (0.31) | — | |
| SCHEMBL20621313 | 0.75 | NOS3 (0.31) | — | |
| SCHEMBL23693838 | 0.73 | HRH4 (0.36) | — | |
| SCHEMBL31043414 | 0.71 | — | — | |
| SCHEMBL23685266 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171492-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-06-10 | — | — | US | disclosed |
| US-10597377-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-03-24 | — | — | US | disclosed |
| US-10351547-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20190002431-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2019-01-03 | — | — | US | disclosed |
| US-9896432-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2018-02-20 | — | — | US | disclosed |
| US-9896432-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20180016252-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2018-01-18 | — | — | US | disclosed |
| US-20180016252-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016252-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | ADRA2A 259/4885ADRA2B 223/4885ADRA2C 316/4885 |
| US-10597377-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | ADRA2A 259/4885ADRA2B 223/4885ADRA2C 316/4885 |
| US-10351547-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | ADRA2A 259/4885ADRA2B 223/4885ADRA2C 316/4885 |
| US-20190002431-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | ADRA2A 259/4885ADRA2B 223/4885ADRA2C 316/4885 |
| US-20210171492-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | ADRA2A 259/4885ADRA2B 223/4885ADRA2C 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.